The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).
 
Desmond Yip
Consulting or Advisory Role - Bayer (Inst); Eisai (Inst); Ipsen (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Seqirus (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Novartis
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Aimmune; Alnylam; Biomarin; Bluebird Bio; Cochlear; CSL Limited; Dova Pharmaceuticals; GW Pharmaceuticals; Juno Therapeutics; Kiadis Pharma; Kite, a Gilead company; Sage Therapeutics; TherapeuticsMD; Vertex
Honoraria - Gilead Sciences; Halozyme; Merck Serono; pfizer; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Pfizer; Sirtex Medical; Targovax
Research Funding - AstraZeneca (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - Bayer; GlaxoSmithKline; Lilly; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Other Relationship - Innate Pharma
 
Mikael Eriksson
Honoraria - Bayer; Clinigen Group; Lilly
Consulting or Advisory Role - Isofol Medical
 
David Espinoza
No Relationships to Disclose
 
Timothy Jay Price
Consulting or Advisory Role - Amgen; Merck Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen
 
Sandrine Marreaud
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
 
Neeltje Steeghs
Research Funding - AB Science (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Kjetil Boye
Consulting or Advisory Role - Bayer
Speakers' Bureau - Lilly
Research Funding - Bayer (Inst); Lilly (Inst)
 
Craig Underhill
No Relationships to Disclose
 
Sayeda Naher
No Relationships to Disclose
 
Martinus Oostendorp
No Relationships to Disclose
 
Val Gebski
No Relationships to Disclose
 
John Simes
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst)
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
Other Relationship - Daiichi Sankyo
 
Heikki Joensuu
Employment - Neutron Therapeutics; Orion
Leadership - Sartar Therapeutics
Stock and Other Ownership Interests - Faron Pharmaceuticals; Orion
Consulting or Advisory Role - Neutron Therapeutics
Patents, Royalties, Other Intellectual Property - Sartar Therapeutics